Angiotensin-Converting Enzyme Inhibitor Initiation and Dose Uptitration in Children With Cardiovascular Disease: A Retrospective Review of Standard Clinical Practice and a Prospective Randomized Clinical Trial

Journal of the American Heart Association

Volumn 5, Issue 5, 2016, Pages

  Roche, S Lucy ^a,c,d   Timberlake, Kathryn ^b,c   Manlhiot, Cedric ^a,c   Balasingam, Mervin ^c   Wilson, Judith ^c   George, Kristen ^c   Mccrindle, Brian W ^a,c   Kantor, Paul F ^a,c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Congenital; Drugs; Heart defects; Heart failure; Pediatrics

Indexed keywords

CAPTOPRIL; ENALAPRIL; RAMIPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZED CHILD; HUMAN; INFANT; INTENSIVE CARE; KIDNEY FUNCTION; MALE; NEWBORN; OPEN STUDY; OPTIMAL DRUG DOSE; PEDIATRIC CARDIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TITRIMETRY; TREATMENT DURATION; TREATMENT RESPONSE; CONGENITAL HEART MALFORMATION; CONGESTIVE CARDIOMYOPATHY; HEART FAILURE; HEART VENTRICLE FUNCTION; PRESCHOOL CHILD; TIME FACTOR;

ADOLESCENT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CARDIOMYOPATHY, DILATED; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART DEFECTS, CONGENITAL; HEART FAILURE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TIME FACTORS; VENTRICULAR DYSFUNCTION;

EID: 85039066341     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.116.003230     Document Type: Article

References (29)

1. Kantor PF, Lougheed J, Dancea A, McGillion M. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. Can J Cardiol. 2013;29:1535-1552.
2. Hsu DT, Pearson GD. Heart failure in children: part II: diagnosis, treatment, and future directions. Circ Heart Fail. 2009;2:490-498.
3. Kirk R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary [Corrected]. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 2014;33:888-909.
4. Momma K. ACE inhibitors in pediatric patients with heart failure. Paediatr Drugs. 2006;8:55-69.
5. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, Berard C, Vaksmann G, Weber S, Bécane H-M. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J. 2007;154:596-602.
6. Chu PY, Campbell MJ, Miller SG, Hill KD. Anti-hypertensive drugs in children and adolescents. World J Cardiol. 2014;6:234-244.
7. Roche SL, O'Sullivan JJ, Kantor PF. Hypertension after pediatric cardiac transplantation: detection, etiology, implications and management. Pediatr Transplant. 2010;14:159-168.
8. Phelps CM, Eshelman J, Cruz ED, Pan Z, Kaufman J. Acute kidney injury after cardiac surgery in infants and children: evaluation of the role of angiotensin-converting enzyme inhibitors. Pediatr Cardiol. 2011;33:1-7.
9. Moffett BS, Goldstein SL, Adusei M, Kuzin J, Mohan P, Mott AR. Risk factors for postoperative acute kidney injury in pediatric cardiac surgery patients receiving angiotensin-converting enzyme inhibitors. Pediatr Crit Care Med. 2011;12:555-559.
10. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GYH, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines, Popescu BA, McDonagh T, Sechtem U. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
11. Stevenson WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-e327.
12. Segura J, Christiansen H, Campo C, Ruilope LM. How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria? Curr Hypertens Rep. 2003;5:426-429.
13. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatr Soc. 2002;50:1297-1300.
14. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104:1985-1991.
15. American Diabetes Association. Executive summary: standards of medical care in diabetes-2012. Diabetes Care. 2012;35(suppl 1):S4-S10.
16. Paediatric Formulary Committee. BNF for Children (BNFC). 2015-2016 ed. London: Pharmaceutical Press; 2015.
17. Lau E. The Hospital for Sick Children Drug Handbook and Formulary. Toronto: LexiComp; 2015.
18. Chevalier RL. Mechanisms of fetal and neonatal renal impairment by pharmacologic inhibition of angiotensin. Curr Med Chem. 2012;19:4572-4580.
19. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. Journal of clinical epidemiology 2010;63:834-840.
20. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
21. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, Kuznetsova T, Laurent S, Mancia G, Morales-Olivas F, Rascher W, Redon J, Schaefer F, Seeman T, Stergiou G, Wühl E, Zanchetti A. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27:1719-1742.
22. Pearson GJ, Cooke C, Simmons WK, Sketris I. Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes. J Clin Pharm Ther. 2001;26:351-361.
23. Lainscak M. Implementation of guidelines for management of heart failure in heart failure clinic: effects beyond pharmacological treatment. Int J Cardiol. 2004;97:411-416.
24. Sinaiko AR, Mirkin BL, Hendrick DA, Green TP. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr. 1983;103:799-805.
25. Shaddy RE. Paediatric heart failure trials and tribulations. Cardiol Young. 2007;17:354-355.
26. Li JS, Cohen-Wolkowiez M, Pasquali SK. Pediatric cardiovascular drug trials, lessons learned. J Cardiovasc Pharmacol. 2011;58:4-8.
27. Wells T, Rippley R, Hogg R, Sakarcan A, Blowey D, Walson P, Vogt B, Delucchi A, Lo MW, Hand E, Panebianco D, Shaw W, Shahinfar S. The pharmacokinetics of enalapril in children and infants with hypertension. J Clin Pharmacol. 2001;41:1064-1074.
28. Dutertre JP, Billaud EM, Autret E, Chantepie A, Oliver I, Laugier J. Inhibition of angiotensin converting enzyme with enalapril maleate in infants with congestive heart failure. Br J Clin Pharmacol. 1993;35:528-530.
29. Scammell AM, Diver MJ. Plasma renin activity in infants with congenital heart disease. Arch Dis Child. 1987;62:1136-1138.